| 1 | A Critical View on New and Future Antidepressants | 2.5 | 7 | Citations (PDF) |
| 2 | Biomarkers of treatment-resistant schizophrenia: A systematic review | 0.0 | 7 | Citations (PDF) |
| 3 | The clinical perspective on late-onset depression in European real-world treatment settings | 1.0 | 5 | Citations (PDF) |
| 4 | Multilingualism and international mental health research–The barriers for non-native speakers of English | 0.0 | 1 | Citations (PDF) |
| 5 | Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics | 3.9 | 18 | Citations (PDF) |
| 6 | Multimodal brain-derived subtypes of Major depressive disorder differentiate patients for anergic symptoms, immune-inflammatory markers, history of childhood trauma and treatment-resistance | 1.0 | 6 | Citations (PDF) |
| 7 | Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets? | 3.0 | 4 | Citations (PDF) |
| 8 | Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank | 4.6 | 17 | Citations (PDF) |
| 9 | Investigation of Psychoactive Medications: Challenges and a Practical and
Scalable New Path | 2.4 | 4 | Citations (PDF) |
| 10 | Mental fatigue in individuals with psychiatric disorders: a scoping review | 3.0 | 27 | Citations (PDF) |
| 11 | Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting | 3.9 | 9 | Citations (PDF) |
| 12 | Age as a moderating factor of treatment resistance in depression | 0.3 | 7 | Citations (PDF) |
| 13 | Anhedonia and Depressive Disorders | 2.5 | 107 | Citations (PDF) |
| 14 | Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta‐analysis | 4.6 | 32 | Citations (PDF) |
| 15 | Emotion dysregulation in bipolar disorder compared to other mental illnesses: a systematic review and meta-analysis | 4.6 | 25 | Citations (PDF) |
| 16 | Volumetric absorptive microsampling for the therapeutic drug monitoring of psychiatric patients treated with cariprazine | 3.2 | 10 | Citations (PDF) |
| 17 | The pharmacological management of treatment-resistant depression: what does the future hold? | 2.3 | 4 | Citations (PDF) |
| 18 | Precision psychiatry | 1.1 | 3 | Citations (PDF) |
| 19 | Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients | 3.9 | 8 | Citations (PDF) |
| 20 | Epigenetic Basis of Psychiatric Disorders: A Narrative Review | 2.4 | 10 | Citations (PDF) |
| 21 | Identifying the Common Genetic Basis of Antidepressant Response | 3.3 | 105 | Citations (PDF) |
| 22 | Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study | 4.8 | 9 | Citations (PDF) |
| 23 | Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors | 1.5 | 215 | Citations (PDF) |
| 24 | Seasonality in Major Depressive Disorder: Effect of Sex and Age | 4.8 | 22 | Citations (PDF) |
| 25 | The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder | 2.0 | 2 | Citations (PDF) |
| 26 | A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response | 1.0 | 41 | Citations (PDF) |
| 27 | Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder | 4.2 | 3 | Citations (PDF) |
| 28 | Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts | 1.7 | 22 | Citations (PDF) |
| 29 | Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review | 1.0 | 13 | Citations (PDF) |
| 30 | The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries | 3.0 | 18 | Citations (PDF) |
| 31 | Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study | 1.0 | 17 | Citations (PDF) |
| 32 | Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders | 5.8 | 72 | Citations (PDF) |
| 33 | Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features | 1.7 | 11 | Citations (PDF) |
| 34 | Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation | 1.8 | 15 | Citations (PDF) |
| 35 | Precision medicine in mood disorders | 0.5 | 3 | Citations (PDF) |
| 36 | The Influence of 5-HTTLPR, BDNF Rs6265 and COMT Rs4680 Polymorphisms on Impulsivity in Bipolar Disorder: The Role of Gender | 2.7 | 14 | Citations (PDF) |
| 37 | Psychopharmacology: past, present and future | 1.7 | 7 | Citations (PDF) |
| 38 | Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence | 1.7 | 18 | Citations (PDF) |
| 39 | Imputed expression of schizophrenia‐associated genes and cognitive measures in patients with schizophrenia | 1.7 | 10 | Citations (PDF) |
| 40 | Depression, antidepressants, and insulin resistance: which link? | 1.0 | 33 | Citations (PDF) |
| 41 | The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis | 1.0 | 11 | Citations (PDF) |
| 42 | Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs | 1.0 | 12 | Citations (PDF) |
| 43 | Persistence of suicidal ideation within acute phase treatment of major depressive disorder: analysis of clinical predictors | 1.7 | 19 | Citations (PDF) |
| 44 | The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs | 4.8 | 3 | Citations (PDF) |
| 45 | The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? | 1.7 | 14 | Citations (PDF) |
| 46 | Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder | 2.6 | 18 | Citations (PDF) |
| 47 | Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder | 1.7 | 8 | Citations (PDF) |
| 48 | The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls | 4.5 | 6 | Citations (PDF) |
| 49 | Clinical Utility of Fluid Biomarker in Depressive Disorder | 2.5 | 8 | Citations (PDF) |
| 50 | Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study | 4.2 | 27 | Citations (PDF) |
| 51 | Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression | 4.8 | 12 | Citations (PDF) |
| 52 | Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder | 4.2 | 63 | Citations (PDF) |
| 53 | Precision psychiatry in clinical practice | 3.0 | 45 | Citations (PDF) |
| 54 | Possible Modulatory Role of ARC Gene Variants in Mood Disorders | 2.5 | 2 | Citations (PDF) |
| 55 | A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat | 2.5 | 3 | Citations (PDF) |
| 56 | Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts | 8.4 | 138 | Citations (PDF) |
| 57 | Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology | 26.1 | 1,312 | Citations (PDF) |
| 58 | The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression | 4.8 | 7 | Citations (PDF) |
| 59 | Genetic underpinnings of sociability in the general population | 5.8 | 48 | Citations (PDF) |
| 60 | The association of childhood trauma, lifetime stressful events and general psychopathological symptoms in euthymic bipolar patients and healthy subjects | 4.8 | 11 | Citations (PDF) |
| 61 | Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing | 5.8 | 44 | Citations (PDF) |
| 62 | Pharmacogenetic‐Guided Treatment of Depression: Real‐World Clinical Applications, Challenges, and Perspectives | 5.2 | 12 | Citations (PDF) |
| 63 | Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment | 2.9 | 9 | Citations (PDF) |
| 64 | Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease | 8.4 | 62 | Citations (PDF) |
| 65 | Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression | 3.9 | 23 | Citations (PDF) |
| 66 | Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis | 4.2 | 158 | Citations (PDF) |
| 67 | Melancholic features in major depression – a European multicenter study | 4.2 | 28 | Citations (PDF) |
| 68 | Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression | 2.5 | 3 | Citations (PDF) |
| 69 | Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels | 2.0 | 4 | Citations (PDF) |
| 70 | Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression | 3.1 | 20 | Citations (PDF) |
| 71 | P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response | 1.0 | 0 | Citations (PDF) |
| 72 | Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study | 2.7 | 4 | Citations (PDF) |
| 73 | Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies | 2.0 | 16 | Citations (PDF) |
| 74 | Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder | 4.8 | 14 | Citations (PDF) |
| 75 | Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes | 10.1 | 129 | Citations (PDF) |
| 76 | Genetics of resilience: Implications from genome‐wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression | 1.8 | 104 | Citations (PDF) |
| 77 | Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly | 3.0 | 15 | Citations (PDF) |
| 78 | Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples | 4.2 | 41 | Citations (PDF) |
| 79 | Cortico-limbic functional connectivity mediates the effect of early life stress on suicidality in bipolar depressed 5-HTTLPR*s carriers | 4.8 | 21 | Citations (PDF) |
| 80 | Pharmacogenetics in Psychiatry: An Update on Clinical Usability | 4.0 | 66 | Citations (PDF) |
| 81 | Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study | 1.0 | 18 | Citations (PDF) |
| 82 | P.141 Topological data analysis for genetic-driven stratification of patients with major depressive disorder | 1.0 | 0 | Citations (PDF) |
| 83 | P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder | 1.0 | 0 | Citations (PDF) |
| 84 | P.335 Drug repositioning for treatment-resistant depression by comparing genetic predictors with known drug targets | 1.0 | 0 | Citations (PDF) |
| 85 | Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment | 1.7 | 30 | Citations (PDF) |
| 86 | Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression | 2.0 | 10 | Citations (PDF) |
| 87 | Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure | 2.0 | 9 | Citations (PDF) |
| 88 | A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping | 5.8 | 48 | Citations (PDF) |
| 89 | Genetic variants associated with psychotic symptoms across psychiatric disorders | 2.0 | 10 | Citations (PDF) |
| 90 | The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins | 1.0 | 11 | Citations (PDF) |
| 91 | New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others | 13.4 | 61 | Citations (PDF) |
| 92 | Antidepressants: Indications, Contraindications, Interactions, and Side Effects 2020, , 1-38 | | 9 | Citations (PDF) |
| 93 | Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future | 2.5 | 28 | Citations (PDF) |
| 94 | <i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders | 2.5 | 8 | Citations (PDF) |
| 95 | How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach | 2.5 | 17 | Citations (PDF) |
| 96 | The Search for Personalized Antidepressant Treatments: What have we Learned and Where are we Going | 1.8 | 2 | Citations (PDF) |
| 97 | The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis | 4.2 | 47 | Citations (PDF) |
| 98 | Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder | 4.2 | 23 | Citations (PDF) |
| 99 | Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice | 3.9 | 135 | Citations (PDF) |
| 100 | Is Pharmacogenetics Useful in Antidepressant Treatment? | 5.2 | 2 | Citations (PDF) |
| 101 | Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone | 1.0 | 128 | Citations (PDF) |
| 102 | F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION | 1.0 | 0 | Citations (PDF) |
| 103 | F128TRANSDIAGNOSTIC EFFECT ON PSYCHOPATHOLOGY BY PSYCHOSES GENES VARIANTS | 1.0 | 0 | Citations (PDF) |
| 104 | 12 GENETIC UNDERPINNINGS OF SOCIABILITY | 1.0 | 2 | Citations (PDF) |
| 105 | SA92THE INFLUENCE OF THE SEROTONIN TRANSPORTER GENE 5-HTTLPR POLYMORPHISM ON SUICIDAL BEHAVIORS: A META-ANALYSIS | 1.0 | 0 | Citations (PDF) |
| 106 | 57 INVESTIGATING THE COMMON GENETIC BASIS OF ANTIDEPRESSANT RESPONSE | 1.0 | 1 | Citations (PDF) |
| 107 | M67 PSYCHIATRIC DISORDERS AND SLC6A4 GENE VARIANTS: POSSIBLE MODULATION OF ALCOHOL DEPENDENCE AND ALZHEIMER'S DISEASE | 1.0 | 0 | Citations (PDF) |
| 108 | Manifesto for an international digital mental health network | 1.9 | 19 | Citations (PDF) |
| 109 | EXPLORATORY FINDINGS MAY IMPLICATE GENE'S VARIANTS, RELATED TO ANTIPSYCHOTIC MECHANISMS OF ACTION, WITH SCHIZOPHRENIA PSYCHOPATHOLOGICAL FEATURES | 1.0 | 0 | Citations (PDF) |
| 110 | SA105A GENOME-WIDE ASSOCIATION STUDY OF TREATMENT-RESISTANT DEPRESSION AND META-ANALYSIS OF THREE INDEPENDENT SAMPLES | 1.0 | 0 | Citations (PDF) |
| 111 | High occupational level is associated with poor response to the treatment of depression: A replication study | 1.0 | 7 | Citations (PDF) |
| 112 | WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION | 1.0 | 0 | Citations (PDF) |
| 113 | P.4.01 C-X-C chemokine signalling is implicated in major depressive disorder in a sample of Korean elderly subjects | 1.0 | 0 | Citations (PDF) |
| 114 | A genome-wide association study of treatment-resistant depression and meta-analysis with STAR*D | 1.0 | 0 | Citations (PDF) |
| 115 | The brief assessment of cognition in affective disorders: Normative data for the Italian population | 4.8 | 9 | Citations (PDF) |
| 116 | Clinical predictors of treatment resistant depression: Replication results from the European multicenter study | 1.0 | 0 | Citations (PDF) |
| 117 | Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression | 4.2 | 24 | Citations (PDF) |
| 118 | Alzheimer's disease and neurotransmission gene variants: focus on their effects on psychiatric comorbidities and inflammatory parameters | 1.0 | 0 | Citations (PDF) |
| 119 | Genome-wide association study identifies 30 loci associated with bipolar disorder | 26.1 | 1,466 | Citations (PDF) |
| 120 | Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study | 1.0 | 26 | Citations (PDF) |
| 121 | The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis | 1.0 | 0 | Citations (PDF) |
| 122 | Temperament and character influence on depression treatment outcome | 4.8 | 40 | Citations (PDF) |
| 123 | Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 124 | Predominant polarity in bipolar disorder patients: The COPE bipolar sample | 4.8 | 25 | Citations (PDF) |
| 125 | Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression | 4.8 | 21 | Citations (PDF) |
| 126 | 58 PREDICTION OF TREATMENT-RESISTANT DEPRESSION USING EXOME SEQUENCE AND GENOME-WIDE DATA | 1.0 | 0 | Citations (PDF) |
| 127 | M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | 1.0 | 0 | Citations (PDF) |
| 128 | ROLE OF 108 SCHIZOPHRENIA-ASSOCIATED LOCI IN MODULATING PSYCHOPATOLOGICAL DIMENSIONS IN SCHIZOPHRENIA AND BIPOLAR DISORDER | 1.0 | 0 | Citations (PDF) |
| 129 | PLEIOTROPIC GENES IN PSYCHIATRY: EFFECTS OF CALCIUM CHANNELS AND THE STRESS-RELATED FKBP5 GENE ON ANTIDEPRESSANT RESPONSE AND TREATMENT RESISTANCE | 1.0 | 0 | Citations (PDF) |
| 130 | P.057 A genetic predictor of treatment-resistant depression using exome sequencing and genome-wide genotyping | 1.0 | 0 | Citations (PDF) |
| 131 | Personalized and precision medicine as informants for treatment management of bipolar disorder | 1.7 | 22 | Citations (PDF) |
| 132 | Attrition in treatment-resistant depression | 1.7 | 2 | Citations (PDF) |
| 133 | Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric DisordersCell, 2019, 179, 1469-1482.e11 | 28.6 | 1,282 | Citations (PDF) |
| 134 | P.021 Social dysfunction in mood disorders and schizophrenia: clinical correlates in four independent samples | 1.0 | 0 | Citations (PDF) |
| 135 | P.321 Clinical parameters associated with augmentation and combination treatment in unipolar depression | 1.0 | 0 | Citations (PDF) |
| 136 | Relating constructs of attention and working memory to social withdrawal in Alzheimer’s disease and schizophrenia: issues regarding paradigm selection | 7.5 | 25 | Citations (PDF) |
| 137 | Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature | 3.1 | 21 | Citations (PDF) |
| 138 | Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples | 2.3 | 66 | Citations (PDF) |
| 139 | Duloxetine plasma level and antidepressant response | 4.2 | 32 | Citations (PDF) |
| 140 | Opinion paper: poor response to treatment of depression in people in high occupational levels | 4.6 | 8 | Citations (PDF) |
| 141 | Quantitative neurosymptomatics: Linking quantitative biology to neuropsychiatry | 7.5 | 11 | Citations (PDF) |
| 142 | Social brain, social dysfunction and social withdrawal | 7.5 | 343 | Citations (PDF) |
| 143 | Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study | 4.6 | 130 | Citations (PDF) |
| 144 | A quantitative approach to neuropsychiatry: The why and the how | 7.5 | 99 | Citations (PDF) |
| 145 | The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives | 2.0 | 57 | Citations (PDF) |
| 146 | Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer’s disease | 2.6 | 12 | Citations (PDF) |
| 147 | Pharmacogenetics and Depression: A Critical Perspective | 1.7 | 24 | Citations (PDF) |
| 148 | Psychotic Features in Patients With Major Depressive Disorder | 2.9 | 47 | Citations (PDF) |
| 149 | Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C, CHRNA7</i> and <i>MAPK1</i> | 2.5 | 13 | Citations (PDF) |
| 150 | Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD) | 2.0 | 76 | Citations (PDF) |
| 151 | Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction | 0.7 | 7 | Citations (PDF) |
| 152 | Highlights on Pharmacogenetics and Pharmacogenomics in Depression 2018, , 3-16 | | 0 | Citations (PDF) |
| 153 | Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD) | 1.0 | 60 | Citations (PDF) |
| 154 | Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study | 4.8 | 8 | Citations (PDF) |
| 155 | Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance | 4.2 | 41 | Citations (PDF) |
| 156 | Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression | 4.8 | 39 | Citations (PDF) |
| 157 | The serotonin transporter and the activity regulated cytoskeleton‐associated protein genes in antidepressant response and resistance: <scp>5‐HTTLPR</scp> and other variants | 2.0 | 8 | Citations (PDF) |
| 158 | Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study | 1.0 | 19 | Citations (PDF) |
| 159 | Brexpiprazole: a step forward for precision medicine in resistant depression | 2.3 | 3 | Citations (PDF) |
| 160 | Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample | 3.5 | 16 | Citations (PDF) |
| 161 | Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials | 4.2 | 46 | Citations (PDF) |
| 162 | Pleiotropic genes in psychiatry: calcium channels and the stress-related FKBP5 gene in antidepressant resistance | 1.0 | 2 | Citations (PDF) |
| 163 | A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder | 2.5 | 41 | Citations (PDF) |
| 164 | The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis | 3.3 | 158 | Citations (PDF) |
| 165 | Pharmacogenetics in Psychiatry | 0.0 | 42 | Citations (PDF) |
| 166 | 22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders | 5.0 | 1 | Citations (PDF) |
| 167 | White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress | 3.7 | 38 | Citations (PDF) |
| 168 | Refining Prediction in Treatment-Resistant Depression | 2.9 | 99 | Citations (PDF) |
| 169 | The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants | 2.5 | 67 | Citations (PDF) |
| 170 | A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial | 2.5 | 58 | Citations (PDF) |
| 171 | Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics | 3.9 | 53 | Citations (PDF) |
| 172 | The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder | 3.5 | 19 | Citations (PDF) |
| 173 | Maoa and Maob polymorphisms and personality traits in suicide attempters and healthy controls: a preliminary study | 3.4 | 7 | Citations (PDF) |
| 174 | Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study | 3.1 | 108 | Citations (PDF) |
| 175 | Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT | 3.1 | 18 | Citations (PDF) |
| 176 | Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance | 3.0 | 24 | Citations (PDF) |
| 177 | Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia | 1.7 | 21 | Citations (PDF) |
| 178 | Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples | 3.2 | 11 | Citations (PDF) |
| 179 | Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples | 3.5 | 4 | Citations (PDF) |
| 180 | The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study | 1.0 | 21 | Citations (PDF) |
| 181 | Nine differentially expressed genes from a post mortem study and their association with suicidal status in a sample of suicide completers, attempters and controls | 3.1 | 7 | Citations (PDF) |
| 182 | ECG Alterations Associated with Psychotropic Drug Use In Clinical Settings: Clinical And Genetic Predictors | 1.0 | 0 | Citations (PDF) |
| 183 | Genes Involved In Neurodevelopment, Neuroplasticity And Bipolar Disorder: Cacna1c, Chrna1 And MAPK1 | 1.0 | 0 | Citations (PDF) |
| 184 | Investigation of Genetic Variants Within Genes Targets of Antipsychotic Response And Their Signal Cascade In Schizophrenia And Antipsychotic Response | 1.0 | 0 | Citations (PDF) |
| 185 | Alzheimer’s Disease And Neurotransmission Gene Variants | 1.0 | 0 | Citations (PDF) |
| 186 | The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study | 2.0 | 10 | Citations (PDF) |
| 187 | Cariprazine specificity profile in the treatment of acute schizophrenia | 1.7 | 29 | Citations (PDF) |
| 188 | Role of 108 schizophrenia‐associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder | 1.8 | 46 | Citations (PDF) |
| 189 | Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials | 1.0 | 0 | Citations (PDF) |
| 190 | Escitalopram plasma levels and antidepressant response | 1.0 | 53 | Citations (PDF) |
| 191 | Prescribing patterns of psychiatric drugs in major depressive disorder – Findings from a large European multicenter, cross-sectional study | 0.3 | 0 | Citations (PDF) |
| 192 | Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response | 3.9 | 80 | Citations (PDF) |
| 193 | Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 194 | Potential genes behind the difference between bipolar I and bipolar II disorder | 1.0 | 0 | Citations (PDF) |
| 195 | Predominant polarity in bipolar disorder – is there a genetic base? | 1.0 | 3 | Citations (PDF) |
| 196 | Genetic variants within key nodes of the cascade of antipsychotic mechanisms: effects on treatment response and schizophrenia psychopathology | 1.0 | 0 | Citations (PDF) |
| 197 | Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 198 | Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role | 2.5 | 7 | Citations (PDF) |
| 199 | Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression | 8.4 | 281 | Citations (PDF) |
| 200 | Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features | 2.5 | 5 | Citations (PDF) |
| 201 | Genetics and pharmacogenetics of mood disorders | 0.7 | 13 | Citations (PDF) |
| 202 | A New Prediction Model for Evaluating Treatment-Resistant Depression | 2.9 | 88 | Citations (PDF) |
| 203 | Evidence based criteria for the antidepressant choice | 0.2 | 0 | Citations (PDF) |
| 204 | Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia | 1.9 | 17 | Citations (PDF) |
| 205 | The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study | 1.7 | 23 | Citations (PDF) |
| 206 | Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples | 1.0 | 0 | Citations (PDF) |
| 207 | ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors | 1.0 | 0 | Citations (PDF) |
| 208 | Epidemiology of psychopharmacological options in unipolar major depression in European tertiary psychiatric treatment centers | 1.0 | 0 | Citations (PDF) |
| 209 | High occupational level is associated with poor response to treatment of depression | 1.0 | 0 | Citations (PDF) |
| 210 | A meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression | 4.8 | 61 | Citations (PDF) |
| 211 | Possible Biomarkers Modulating Haloperidol Efficacy and/or Tolerability | 1.8 | 2 | Citations (PDF) |
| 212 | Clinical factors related to schizophrenia relapse | 3.0 | 39 | Citations (PDF) |
| 213 | HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis | 2.0 | 29 | Citations (PDF) |
| 214 | Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review | 3.4 | 199 | Citations (PDF) |
| 215 | Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease | 0.8 | 17 | Citations (PDF) |
| 216 | High occupational level is associated with poor response to treatment of depression | 1.0 | 9 | Citations (PDF) |
| 217 | Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial | 3.3 | 18 | Citations (PDF) |
| 218 | Nine differentially expressed genes from a post mortem study and their association with suicidal status in a sample of suicide completers, attempters and controls | 1.0 | 0 | Citations (PDF) |
| 219 | Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study | 1.0 | 61 | Citations (PDF) |
| 220 | Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? | 5.2 | 0 | Citations (PDF) |
| 221 | Progress and prospects in pharmacogenetics of antidepressant drugs | 2.8 | 34 | Citations (PDF) |
| 222 | Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder | 2.0 | 12 | Citations (PDF) |
| 223 | Bipolar II disorder as a risk factor for postpartum depression | 4.8 | 34 | Citations (PDF) |
| 224 | Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway | 3.3 | 26 | Citations (PDF) |
| 225 | Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis | 1.0 | 61 | Citations (PDF) |
| 226 | 5-HTTLPR and gender differences in affective disorders: A systematic review | 4.8 | 63 | Citations (PDF) |
| 227 | The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades | 4.8 | 14 | Citations (PDF) |
| 228 | Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials | 3.0 | 29 | Citations (PDF) |
| 229 | Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs 2016, , 39-54 | | 1 | Citations (PDF) |
| 230 | Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study | 4.8 | 89 | Citations (PDF) |
| 231 | Genetics of long-term treatment outcome in bipolar disorder | 4.2 | 44 | Citations (PDF) |
| 232 | Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors | 1.7 | 15 | Citations (PDF) |
| 233 | The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs 2016, , 121-146 | | 0 | Citations (PDF) |
| 234 | Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant, and Mood-Stabilizing Drugs 2016, , 111-117 | | 0 | Citations (PDF) |
| 235 | P1.a.023 Impact of a SNP in SIGMAR1 on major depression, bipolar disorder and treatment response | 1.0 | 0 | Citations (PDF) |
| 236 | P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review | 1.0 | 0 | Citations (PDF) |
| 237 | P.1.a.015 Brain-Derived Neurotrophic Factor (BDNF) genetic pathway and bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 238 | P1.a.013 Effect of HTR7 gene variants on the efficacy of second-generation antipsychotics with 5-HT7R antagonism in Japanese schizophrenia patients | 1.0 | 0 | Citations (PDF) |
| 239 | Low-activity alleles of the MAOA gene are associated with measures of hostility | 1.4 | 1 | Citations (PDF) |
| 240 | Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder | 1.3 | 16 | Citations (PDF) |
| 241 | CACNA1C gene and schizophrenia | 1.4 | 23 | Citations (PDF) |
| 242 | HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia | 2.0 | 23 | Citations (PDF) |
| 243 | Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression | 2.0 | 53 | Citations (PDF) |
| 244 | Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications | 6.3 | 77 | Citations (PDF) |
| 245 | Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression | 4.8 | 42 | Citations (PDF) |
| 246 | Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review | 10.1 | 175 | Citations (PDF) |
| 247 | P.1.a.006 CACNA1C gene and schizophrenia: A case-control and pharmacogenetic study | 1.0 | 1 | Citations (PDF) |
| 248 | Cognitive markers of psychotic unipolar depression: A meta-analytic study | 4.8 | 56 | Citations (PDF) |
| 249 | The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression | 1.0 | 90 | Citations (PDF) |
| 250 | A molecular pathway analysis informs the genetic background at risk for schizophrenia | 4.2 | 21 | Citations (PDF) |
| 251 | Genetic Variability in CYP2E1 and Catalase Gene Among Currently and Formerly Alcohol-Dependent Male Subjects | 1.9 | 30 | Citations (PDF) |
| 252 | What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram | 3.9 | 15 | Citations (PDF) |
| 253 | <i>CHL1</i>
,
<i>ITGB3</i>
and
<i>SLC6A4</i>
Gene Expression and Antidepressant Drug Response: Results from the Munich Antidepressant Response Signature (MARS) Study | 1.8 | 22 | Citations (PDF) |
| 254 | The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression | 0.3 | 504 | Citations (PDF) |
| 255 | Reduced Frontal Cortical Thickness in Generalized Anxiety Disorder | 0.3 | 1 | Citations (PDF) |
| 256 | Genetic variability in tryptophan hydroxylase 2 gene in alcohol dependence and alcohol-related psychopathological symptoms | 2.0 | 13 | Citations (PDF) |
| 257 | Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls | 3.4 | 26 | Citations (PDF) |
| 258 | Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial | 3.0 | 6 | Citations (PDF) |
| 259 | Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder | 2.4 | 58 | Citations (PDF) |
| 260 | The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia | 4.5 | 12 | Citations (PDF) |
| 261 | Neuronal cell adhesion genes and antidepressant response in three independent samples | 3.1 | 38 | Citations (PDF) |
| 262 | Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder | 4.8 | 47 | Citations (PDF) |
| 263 | Predictors of switch from depression to mania in bipolar disorder | 3.1 | 31 | Citations (PDF) |
| 264 | Il trattamento antidepressivo: effetti sul peso corporeo | 0.0 | 0 | Citations (PDF) |
| 265 | Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs | 5.8 | 21 | Citations (PDF) |
| 266 | Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment | 3.4 | 75 | Citations (PDF) |
| 267 | Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis | 3.1 | 54 | Citations (PDF) |
| 268 | Persistent benefits of slow titration of paroxetine in a six‐month follow‐up | 2.0 | 2 | Citations (PDF) |
| 269 | P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 270 | P.2.d.034 How to improve bipolar disorder management? A novel prospective: the use of biomarkers | 1.0 | 0 | Citations (PDF) |
| 271 | P.3.d.038 The effects of risperidone long-acting injection versus paliperidone palmitate on cognitive and social function in schizophrenia – an open pilot randomised controlled trial | 1.0 | 0 | Citations (PDF) |
| 272 | P.1.a.007 Four polymorphisms of SLC6A4 are novel predictors of SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4 | 1.0 | 1 | Citations (PDF) |
| 273 | P.2.f.006 Temperament and character inventory and response to antidepressant treatment | 1.0 | 0 | Citations (PDF) |
| 274 | Neuroticism, social network, stressful life events: Association with mood disorders, depressive symptoms and suicidal ideation in a community sample of women | 3.4 | 40 | Citations (PDF) |
| 275 | Association study ofCREB1polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression | 1.8 | 8 | Citations (PDF) |
| 276 | Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis | 3.7 | 34 | Citations (PDF) |
| 277 | Clinical and genetic factors associated with suicide in mood disorder patients | 3.0 | 38 | Citations (PDF) |
| 278 | Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders | 3.0 | 10 | Citations (PDF) |
| 279 | CRY1 Variations Impacts on the Depressive Relapse Rate in a Sample of Bipolar Patients | 1.7 | 15 | Citations (PDF) |
| 280 | Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample | 2.5 | 16 | Citations (PDF) |
| 281 | Meet the Editorial Board: | 2.5 | 0 | Citations (PDF) |
| 282 | Trait-aggressiveness and impulsivity: Role of psychological resilience and childhood trauma in a sample of male prisoners | 1.8 | 26 | Citations (PDF) |
| 283 | Benefit of slow titration of paroxetine to treat depression in the elderly | 2.0 | 6 | Citations (PDF) |
| 284 | Pharmacogenetics of Antidepressant Drugs 2014, , 543-562 | | 0 | Citations (PDF) |
| 285 | Serious suicidal behaviors: Socio-demographic and clinical features in a multinational, multicenter sample | 1.8 | 21 | Citations (PDF) |
| 286 | Clozapine augmentation with amisulpride | 2.4 | 6 | Citations (PDF) |
| 287 | The genetics of vascular incidents associated with second-generation antipsychotic administration | 3.0 | 1 | Citations (PDF) |
| 288 | Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment | 2.0 | 11 | Citations (PDF) |
| 289 | Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment | 1.3 | 30 | Citations (PDF) |
| 290 | Psychological Mechanisms of Mindfulness-Based Interventions | 1.4 | 108 | Citations (PDF) |
| 291 | Genetic modulation of personality traits | 1.7 | 85 | Citations (PDF) |
| 292 | Quetiapine Extended Release | 2.0 | 4 | Citations (PDF) |
| 293 | Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials | 2.0 | 34 | Citations (PDF) |
| 294 | Genomewide interaction and enrichment analysis on antidepressant response | 4.6 | 8 | Citations (PDF) |
| 295 | P.1.001 Genes involved in neuroplasticity and short-term response to antidepressant drugs: a complex interplay between genetics and environment | 1.0 | 0 | Citations (PDF) |
| 296 | P.3.015 Socio-demographic and clinical predictors of antidepressant remission and response in treatment resistant depression | 1.0 | 0 | Citations (PDF) |
| 297 | The association of personality trait on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: An exploratory study | 2.0 | 36 | Citations (PDF) |
| 298 | Family history of a mood disorder indicates a more severe bipolar disorder | 4.8 | 36 | Citations (PDF) |
| 299 | P.2.d.031 Predictors for manic switch at depressive episodes in bipolar disorder: the Systematic Treatment Enhancement Program for Bipolar Disorder | 1.0 | 0 | Citations (PDF) |
| 300 | P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis | 1.0 | 0 | Citations (PDF) |
| 301 | P.1.a.012 New insights from cell adhesion molecules in antidepressant action: role of ITGB3 and GAP43 genes | 1.0 | 0 | Citations (PDF) |
| 302 | P.2.d.048 COMT modulates working memory and impulsivity control in bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 303 | Are Mindfulness-Based Interventions Effective for Substance Use Disorders? A Systematic Review of the Evidence | 1.7 | 291 | Citations (PDF) |
| 304 | P.2.f.011 Socio-demographic and clinical predictors of non response/non remission in treatment resistant depressed patients: a systematic review | 1.0 | 0 | Citations (PDF) |
| 305 | P.2.b.013 Socio-demographic and clinical predictors of antidepressant remission and response in treatment resistant depression | 1.0 | 0 | Citations (PDF) |
| 306 | P.2.b.019 The complexity of genetic effects in pharmacogenetics: focus on neuroplasticity, environmental stress and response to antidepressants | 1.0 | 0 | Citations (PDF) |
| 307 | P.3.b.016 Onset age in schizophrenia spectrum disorders: complex interactions between genetic and environmental factors | 1.0 | 0 | Citations (PDF) |
| 308 | P.2.b.035 The combined effect of genetic polymorphisms and clinical parameters on treatment response and resistance in major depressive disorder | 1.0 | 0 | Citations (PDF) |
| 309 | Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder | 3.6 | 19 | Citations (PDF) |
| 310 | DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy | 4.8 | 19 | Citations (PDF) |
| 311 | Effects of antipsychotic drugs on insight in schizophrenia | 3.4 | 14 | Citations (PDF) |
| 312 | PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway | 3.1 | 44 | Citations (PDF) |
| 313 | Lack of influence of rs4680 (<i>COMT</i>) and rs6276 (<i>DRD2</i>) on diagnosis and clinical outcomes in patients with major depression | 3.0 | 21 | Citations (PDF) |
| 314 | P.6.f.008 Does genetics predict severity of gambling disorder? A preliminary study on an Italian sample of gamblers | 1.0 | 0 | Citations (PDF) |
| 315 | P.6.b.002 Oxidative stress and expression of alcohol related psychopathological symptoms in alcohol dependent subjects | 1.0 | 0 | Citations (PDF) |
| 316 | P.3.d.027 Does medication history profile affect treatment response of antagonist and partial agonist at the D2 receptors in schizophrenia? | 1.0 | 0 | Citations (PDF) |
| 317 | P.3.013 Genetic variants in ST8SIA2 gene influence treatment outcome in treatment resistant depression: a European multicenter study | 1.0 | 1 | Citations (PDF) |
| 318 | Modulation of a number of genes on personality traits in a sample of healthy subjects | 2.0 | 6 | Citations (PDF) |
| 319 | HSP70 polymorphisms in first psychotic episode drug-naïve schizophrenic patients | 4.6 | 14 | Citations (PDF) |
| 320 | Family history of major depression and residual symptoms in responder and non-responder depressed patients | 4.5 | 9 | Citations (PDF) |
| 321 | P.3.018 Insomnia and somnolence induced by second-generation antidepressants during the treatment of major depression: a meta-analysis | 1.0 | 0 | Citations (PDF) |
| 322 | Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder | 3.4 | 9 | Citations (PDF) |
| 323 | P.1.014 PPP3CC: a new candidate gene in antidepressant response | 1.0 | 0 | Citations (PDF) |
| 324 | The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder | 3.1 | 32 | Citations (PDF) |
| 325 | From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment | 3.2 | 47 | Citations (PDF) |
| 326 | Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients | 3.6 | 14 | Citations (PDF) |
| 327 | A model to investigate SNPs’ interaction in GWAS studies | 3.6 | 3 | Citations (PDF) |
| 328 | Personalized therapies in psychiatry: promises, pitfalls and perspectives | 3.6 | 10 | Citations (PDF) |
| 329 | A molecular pathway analysis of the glutamatergic–monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment | 3.6 | 3 | Citations (PDF) |
| 330 | Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder | 1.7 | 13 | Citations (PDF) |
| 331 | Epistatic Interactions between CREB and CREM Variants in Affective Disorder | 1.7 | 3 | Citations (PDF) |
| 332 | Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment | 3.0 | 53 | Citations (PDF) |
| 333 | Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients | 4.2 | 40 | Citations (PDF) |
| 334 | Gene environment interaction studies in depression and suicidal behavior: An update | 7.5 | 153 | Citations (PDF) |
| 335 | Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer’s disease in two independent European samples | 3.6 | 34 | Citations (PDF) |
| 336 | Serotonergic genes and suicide: A systematic review | 1.0 | 119 | Citations (PDF) |
| 337 | Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients | 4.8 | 17 | Citations (PDF) |
| 338 | P.3.d.022 Pharmacological treatment of acute agitation in schizophrenia | 1.0 | 0 | Citations (PDF) |
| 339 | Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder | 3.4 | 25 | Citations (PDF) |
| 340 | The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders | 10.1 | 675 | Citations (PDF) |
| 341 | Genetic modulation of borderline personality disorder: Systematic review and meta-analysis | 3.1 | 45 | Citations (PDF) |
| 342 | Mindfulness: Top–down or bottom–up emotion regulation strategy? | 10.5 | 399 | Citations (PDF) |
| 343 | Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research | 1.8 | 80 | Citations (PDF) |
| 344 | The 5‐HTTLPR Polymorphism and Posttraumatic Stress Disorder: A Meta‐Analysis | 2.3 | 89 | Citations (PDF) |
| 345 | The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes | 7.5 | 99 | Citations (PDF) |
| 346 | Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder | 3.1 | 50 | Citations (PDF) |
| 347 | Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia | 0.7 | 8 | Citations (PDF) |
| 348 | Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode | 3.1 | 35 | Citations (PDF) |
| 349 | Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: A principal component analysis of lifetime pharmacological and biophysic treatment options | 1.0 | 30 | Citations (PDF) |
| 350 | Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR⁎D) trial | 1.0 | 12 | Citations (PDF) |
| 351 | P.1.a.021 A molecular pathway analysis of the genes in 22q11.2 provides information on the genetic structure of psychosis | 1.0 | 0 | Citations (PDF) |
| 352 | P.1.a.022 Role of phospholipases in response to treatment. Data from the STEP-BD study | 1.0 | 0 | Citations (PDF) |
| 353 | S.25.03 Pharmacogenetics of efficacy and treatment side effects in bipolar disorder | 1.0 | 0 | Citations (PDF) |
| 354 | P.2.f.015 A prospective study of escitalopram in treatment resistant depression not responding to venlafaxine | 1.0 | 0 | Citations (PDF) |
| 355 | P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples | 1.0 | 0 | Citations (PDF) |
| 356 | Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder | 1.0 | 33 | Citations (PDF) |
| 357 | Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR⁎D | 1.0 | 26 | Citations (PDF) |
| 358 | P.3.a.005 A deeper look onto schizophrenia mechanisms. Association with immunological related pathway | 1.0 | 0 | Citations (PDF) |
| 359 | AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment | 1.0 | 29 | Citations (PDF) |
| 360 | Clinical features and drug induced side effects in early versus late antidepressant responders | 3.1 | 29 | Citations (PDF) |
| 361 | Antidepressants in elderly: Metaregression of double-blind, randomized clinical trials | 4.8 | 82 | Citations (PDF) |
| 362 | P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression | 1.0 | 0 | Citations (PDF) |
| 363 | P.2.f.025 Specificity profile of venlafaxine and sertraline in major depression: meta-regression of double-blind, randomized clinical trials | 1.0 | 0 | Citations (PDF) |
| 364 | Authors' reply to “Recommendations for conducting mindfulness based cognitive therapy trials” | 3.4 | 0 | Citations (PDF) |
| 365 | P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples | 1.0 | 0 | Citations (PDF) |
| 366 | P.2.c.010 The inflammatory genetic background and genetically disruption of lithium related molecular pathways in bipolar disorder patients | 1.0 | 0 | Citations (PDF) |
| 367 | Social adjustment among treatment responder patients with mood disorders | 4.8 | 3 | Citations (PDF) |
| 368 | P.2.b.026 Social adjustment among therapy responder patients with mood disorders | 1.0 | 0 | Citations (PDF) |
| 369 | Shared genetics among major psychiatric disorders | 14.8 | 72 | Citations (PDF) |
| 370 | Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability | 4.8 | 17 | Citations (PDF) |
| 371 | Pharmacogenetics in major depression: A comprehensive meta-analysis | 4.2 | 181 | Citations (PDF) |
| 372 | Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples | 6.0 | 19 | Citations (PDF) |
| 373 | Impact of 5-HTTLPR Polymorphism on Alexithymia in Alcoholic Patients After Detoxification Treatment | 2.2 | 4 | Citations (PDF) |
| 374 | Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder | 1.4 | 9 | Citations (PDF) |
| 375 | Newer antidepressants and panic disorder | 1.7 | 58 | Citations (PDF) |
| 376 | A Genetic Dissection of Antipsychotic Induced Movement Disorders | 2.5 | 8 | Citations (PDF) |
| 377 | 5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy | 2.0 | 12 | Citations (PDF) |
| 378 | Potential Benefits of Slow Titration of Paroxetine Treatment in an Elderly Population | 2.0 | 2 | Citations (PDF) |
| 379 | Influence of differentially expressed genes from suicide post-mortem study on personality traits as endophenotypes on healthy subjects and suicide attempters | 3.0 | 11 | Citations (PDF) |
| 380 | Genetics of Serotonin Receptors and Depression: State of the Art | 2.0 | 30 | Citations (PDF) |
| 381 | Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines | 1.5 | 14 | Citations (PDF) |
| 382 | No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression | 1.7 | 23 | Citations (PDF) |
| 383 | A Genetic Dissection of Antipsychotic Induced Movement Disorders | 2.5 | 2 | Citations (PDF) |
| 384 | Predicting Response to Lithium in Mood Disorders | 1.3 | 12 | Citations (PDF) |
| 385 | Aripiprazole in the Treatment of Depressive and Anxiety Disorders | 6.8 | 66 | Citations (PDF) |
| 386 | Predictors of Early Worsening after Switch to Aripiprazole | 2.3 | 14 | Citations (PDF) |
| 387 | Clinical and Demographic Predictors of Improvement during Duloxetine Treatment in Patients with Major Depression | 2.3 | 12 | Citations (PDF) |
| 388 | Bipolar disorder: “pure” versus mixed depression over a 1-year follow-up | 3.0 | 8 | Citations (PDF) |
| 389 | Mindfulness-Based Cognitive Therapy Versus Psycho-Education for Patients with Major Depression Who Did Not Achieve Remission Following Antidepressant Treatment: A Preliminary Analysis | 2.5 | 54 | Citations (PDF) |
| 390 | Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis | 1.5 | 13 | Citations (PDF) |
| 391 | Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings | 2.4 | 25 | Citations (PDF) |
| 392 | P.2.a.011 Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients | 1.0 | 0 | Citations (PDF) |
| 393 | P.3.c.044 Influence of ANKK1 and DRD2 gene polymorphisms in response to haloperidol | 1.0 | 0 | Citations (PDF) |
| 394 | Clozapine resistance: Augmentation strategies | 1.0 | 130 | Citations (PDF) |
| 395 | The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder — A European Multicenter Study | 1.0 | 39 | Citations (PDF) |
| 396 | Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy | 1.0 | 302 | Citations (PDF) |
| 397 | European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings | 1.0 | 121 | Citations (PDF) |
| 398 | Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder | 3.4 | 26 | Citations (PDF) |
| 399 | Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features | 3.4 | 164 | Citations (PDF) |
| 400 | Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients | 3.4 | 114 | Citations (PDF) |
| 401 | Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome | 4.8 | 22 | Citations (PDF) |
| 402 | Case–control association study ofGRIA1,GRIA2andGRIA4polymorphisms in bipolar disorder | 3.0 | 10 | Citations (PDF) |
| 403 | <i>DAOA</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder | 1.4 | 5 | Citations (PDF) |
| 404 | Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries | 4.2 | 36 | Citations (PDF) |
| 405 | Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia | 2.0 | 19 | Citations (PDF) |
| 406 | Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia | 2.0 | 9 | Citations (PDF) |
| 407 | Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression | 2.0 | 23 | Citations (PDF) |
| 408 | Generalized tonic–clonic seizure secondary to duloxetine poisoning: A short report with favorable out come | 3.9 | 10 | Citations (PDF) |
| 409 | Depression across mood disorders: review and analysis in a clinical sample | 4.5 | 39 | Citations (PDF) |
| 410 | Pharmacogenetics of antidepressants and mood stabilizers | 0.0 | 10 | Citations (PDF) |
| 411 | The 3111T/C Polymorphism Interacts With Stressful Life Events to Influence Patterns of Sleep in Females | 2.0 | 35 | Citations (PDF) |
| 412 | The role of serotonergic genes and environmental stress on the development of depressive symptoms and neuroticism | 4.8 | 37 | Citations (PDF) |
| 413 | Paroxetine for the treatment of depression: a critical update | 2.3 | 179 | Citations (PDF) |
| 414 | The challenge of uncovering the genetics of anxiety | 4.6 | 3 | Citations (PDF) |
| 415 | MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls | 3.0 | 37 | Citations (PDF) |
| 416 | Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder | 3.0 | 25 | Citations (PDF) |
| 417 | The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder | 3.0 | 106 | Citations (PDF) |
| 418 | Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol | 3.0 | 16 | Citations (PDF) |
| 419 | The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder | 3.0 | 19 | Citations (PDF) |
| 420 | No Association of a Set of Candidate Genes on Haloperidol Side Effects | 2.5 | 7 | Citations (PDF) |
| 421 | DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes | 3.0 | 4 | Citations (PDF) |
| 422 | Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study | 3.9 | 44 | Citations (PDF) |
| 423 | FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD | 0.3 | 0 | Citations (PDF) |
| 424 | Clock genes and mood disorders: Which role? | 0.3 | 0 | Citations (PDF) |
| 425 | Mindfulness-Based Interventions for Chronic Pain: A Systematic Review of the Evidence | 2.5 | 307 | Citations (PDF) |
| 426 | The<i>CLOCK</i>Gene and Mood Disorders: A Case-Control Study and Meta-analysis | 2.0 | 38 | Citations (PDF) |
| 427 | Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings | 10.5 | 1,084 | Citations (PDF) |
| 428 | COMT and age at onset in mood disorders: A replication and extension study | 2.0 | 33 | Citations (PDF) |
| 429 | The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes | 6.1 | 63 | Citations (PDF) |
| 430 | Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects | 4.2 | 6 | Citations (PDF) |
| 431 | Antidepressants, present and future | 4.2 | 1 | Citations (PDF) |
| 432 | Mechanisms of antidepressant action: An integrated dopaminergic perspective | 4.2 | 40 | Citations (PDF) |
| 433 | Mindfulness based cognitive therapy for psychiatric disorders: A systematic review and meta-analysis | 3.4 | 562 | Citations (PDF) |
| 434 | No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression | 3.4 | 10 | Citations (PDF) |
| 435 | Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia | 3.4 | 42 | Citations (PDF) |
| 436 | The genetics of antipsychotic induced tremors: A genome‐wide pathway analysis on the STEP‐BD SCP sample | 1.8 | 20 | Citations (PDF) |
| 437 | E.02.02 Pitfalls, problems and future | 1.0 | 0 | Citations (PDF) |
| 438 | P.2.c.011 Is pharmacogenetic testing ready for antidepressant treatment? A costeffectiveness simulation | 1.0 | 1 | Citations (PDF) |
| 439 | P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study | 1.0 | 0 | Citations (PDF) |
| 440 | P.2.e.025 Bipolar depression: quetiapine extended release effectiveness | 1.0 | 0 | Citations (PDF) |
| 441 | P.3.c.055 Clozapine resistance: augmentation strategies | 1.0 | 3 | Citations (PDF) |
| 442 | A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders | 3.9 | 41 | Citations (PDF) |
| 443 | A protective genetic variant for adverse environments? The role of childhood traumas and serotonin transporter gene on resilience and depressive severity in a high-risk population | 0.3 | 45 | Citations (PDF) |
| 444 | Sociodemographic Features Predict Antidepressant Trajectories of Response in Diverse Antidepressant Pharmacotreatment Environments | 2.0 | 11 | Citations (PDF) |
| 445 | Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression | 2.0 | 104 | Citations (PDF) |
| 446 | Self-Harm in Prisoners | 0.7 | 22 | Citations (PDF) |
| 447 | Pharmacogenetics of Antidepressants | 4.0 | 80 | Citations (PDF) |
| 448 | Is cognitive behavioural therapy an effective complement to antidepressants in adolescents? A meta-analysis | 2.3 | 17 | Citations (PDF) |
| 449 | Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study | 3.1 | 137 | Citations (PDF) |
| 450 | The influence of childhood trauma on the onset and repetition of suicidal behavior: An investigation in a high risk sample of male prisoners | 3.1 | 73 | Citations (PDF) |
| 451 | A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression | 4.8 | 48 | Citations (PDF) |
| 452 | Specificity profile of paroxetine in major depressive disorder: Meta-regression of double-blind, randomized clinical trials | 4.8 | 26 | Citations (PDF) |
| 453 | Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features | 4.8 | 31 | Citations (PDF) |
| 454 | The 5‐HTTLPR polymorphism and eating disorders: A meta‐analysis | 4.5 | 81 | Citations (PDF) |
| 455 | Pharmacogenomics of Psychotropic Drugs | 1.8 | 2 | Citations (PDF) |
| 456 | Safety and Tolerability of Lamotrigine | 1.2 | 57 | Citations (PDF) |
| 457 | Neuro-imaging of mindfulness meditations: implications for clinical practice | 4.4 | 18 | Citations (PDF) |
| 458 | Factors associated with the course of symptoms in bipolar disorder during a 1-year follow-up: Depression vs. sub-threshold mixed state | 1.8 | 24 | Citations (PDF) |
| 459 | Pharmacogenetics of antidepressant response | 2.4 | 158 | Citations (PDF) |
| 460 | Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder | 3.0 | 34 | Citations (PDF) |
| 461 | Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics | 3.0 | 32 | Citations (PDF) |
| 462 | Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol | 1.3 | 23 | Citations (PDF) |
| 463 | Pharmacogenetics of antipsychotics: focus on the glutamatergic system | 3.3 | 0 | Citations (PDF) |
| 464 | Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study | 1.7 | 24 | Citations (PDF) |
| 465 | Vitamin B12 Levels in Alzheimer's Disease: Association with Clinical Features and Cytokine Production | 2.7 | 45 | Citations (PDF) |
| 466 | The use of the defence style questionnaire in major depressive and panic disorders: A comprehensive meta‐analysis | 2.4 | 53 | Citations (PDF) |
| 467 | Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment | 3.1 | 23 | Citations (PDF) |
| 468 | Correlation of a set of gene variants, life events and personality features on adult ADHD severity | 3.1 | 25 | Citations (PDF) |
| 469 | APOE epsilon‐4 allele and cytokine production in Alzheimer's disease | 2.4 | 35 | Citations (PDF) |
| 470 | Investigation of an epistastic effect between a set of TAAR6 and HSP‐70 genes variations and major mood disorders | 1.8 | 15 | Citations (PDF) |
| 471 | Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link? | 2.3 | 38 | Citations (PDF) |
| 472 | Weight gain in antipsychotic-naive patients: a review and meta-analysis | 4.6 | 98 | Citations (PDF) |
| 473 | No influence of<i>SLC6A3</i>40 base VNTR polymorphism on the response to risperidone | 3.0 | 2 | Citations (PDF) |
| 474 | T3111C CLOCK SINGLE NUCLEOTIDE POLYMORPHISM AND MOOD DISORDERS: A META-ANALYSIS | 2.0 | 23 | Citations (PDF) |
| 475 | Analysis of requirements and specifications for a monitoring system to support the self-management of dementia patients at home 2010, , 1-8 | | 3 | Citations (PDF) |
| 476 | A systematic review of neurobiological and clinical features of mindfulness meditations | 4.6 | 598 | Citations (PDF) |
| 477 | METHODS FOR OBTAINING CLINICALLY USEFUL PHARMACOGENETIC PREDICTORS; AN EXAMPLE OF A DETAILED INVESTIGATION IN AN HALOPERIDOL TREATED SAMPLE | 2.4 | 0 | Citations (PDF) |
| 478 | MDR1 gene polymorphisms and response to acute risperidone treatment | 4.2 | 36 | Citations (PDF) |
| 479 | Quetiapine XR: Current status for the treatment of major depressive disorder | 4.2 | 44 | Citations (PDF) |
| 480 | Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits | 3.4 | 10 | Citations (PDF) |
| 481 | TAAR6 variations possibly associated with antidepressant response and suicidal behavior | 3.4 | 21 | Citations (PDF) |
| 482 | Excessive daytime sleepiness in depressed women | 3.4 | 9 | Citations (PDF) |
| 483 | Further evidence supporting the association between 5HTR2C gene and bipolar disorder | 3.4 | 8 | Citations (PDF) |
| 484 | Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole | 3.4 | 9 | Citations (PDF) |
| 485 | P.1.003 Clinical and genetic predictors of worsening after aripiprazole switch: results from a randomised open study | 1.0 | 0 | Citations (PDF) |
| 486 | P.1.005 Glutamatergic gene variants impact the side effects and antipsychotic efficacy of haloperidol | 1.0 | 0 | Citations (PDF) |
| 487 | S.21.01 Weight gain and antidepressants: a meta-analysis clearly differentiates SSRIs differences | 1.0 | 0 | Citations (PDF) |
| 488 | P.1.a.002 DTNBP1, HSPs and TAAR6 variations influence schizophrenic phenotype and treatment response | 1.0 | 0 | Citations (PDF) |
| 489 | P.3.b.007 Epistasis between variations located in TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotics | 1.0 | 0 | Citations (PDF) |
| 490 | P.3.c.065 Comparison of multifactor dimensionality reduction (MDR) and neural network analysis: serotonergic system genes and antipsychotic response | 1.0 | 0 | Citations (PDF) |
| 491 | Antidepressants in healthy subjects: What are the psychotropic/psychological effects? | 1.0 | 63 | Citations (PDF) |
| 492 | <i>3111T/C CLOCK</i>GENE POLYMORPHISM IS NOT ASSOCIATED WITH SLEEP DISTURBANCES IN UNTREATED DEPRESSED PATIENTS | 2.0 | 36 | Citations (PDF) |
| 493 | No association between genetic markers in<i>BDNF</i>gene and lithium prophylaxis in a Greek sample | 3.0 | 8 | Citations (PDF) |
| 494 | Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment | 3.0 | 2 | Citations (PDF) |
| 495 | Antidepressants and Body Weight | 2.9 | 562 | Citations (PDF) |
| 496 | Effects of antidepressants on gene expression 2010, , 7-21 | | 0 | Citations (PDF) |
| 497 | Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features | 3.1 | 10 | Citations (PDF) |
| 498 | Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Sinthase Kinase 3 Beta (GSK-3 Beta) | 2.5 | 31 | Citations (PDF) |
| 499 | The 8th Annual Pharmacogenetics in Psychiatry Meeting Report | 3.1 | 5 | Citations (PDF) |
| 500 | Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls | 3.1 | 43 | Citations (PDF) |
| 501 | Personality and attempted suicide. Analysis of anger, aggression and impulsivity | 3.1 | 177 | Citations (PDF) |
| 502 | Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up | 4.8 | 80 | Citations (PDF) |
| 503 | Depressive symptomatology is influenced by chronotypes | 4.8 | 191 | Citations (PDF) |
| 504 | Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients | 4.8 | 39 | Citations (PDF) |
| 505 | Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder | 1.8 | 98 | Citations (PDF) |
| 506 | Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects? | 1.8 | 10 | Citations (PDF) |
| 507 | Focus on HTR2C: A possible suggestion for genetic studies of complex disorders | 1.8 | 56 | Citations (PDF) |
| 508 | Dysbindin gene (DTNBP1) and schizophrenia in Korean population | 3.0 | 23 | Citations (PDF) |
| 509 | Schizophrenia: genetics, prevention and rehabilitation | 2.3 | 10 | Citations (PDF) |
| 510 | Thyroid hormones affect recovery from depression during antidepressant treatment | 3.2 | 24 | Citations (PDF) |
| 511 | Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects | 6.8 | 69 | Citations (PDF) |
| 512 | TPH2 gene variants and anxiety during alcohol detoxification outcome | 3.4 | 10 | Citations (PDF) |
| 513 | 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients | 3.4 | 28 | Citations (PDF) |
| 514 | Influence of TAAR6 polymorphisms on response to aripiprazole | 4.2 | 9 | Citations (PDF) |
| 515 | TAAR 6 and HSP-70 variations associated with bipolar disorder | 2.0 | 15 | Citations (PDF) |
| 516 | Association between the estrogen receptor TA polymorphism and Harm avoidance | 2.0 | 16 | Citations (PDF) |
| 517 | Are Noradrenergic Antidepressants a Valuable Choice in the Treatment of Panic Disorder? A Review and Meta Analysis | 0.3 | 0 | Citations (PDF) |
| 518 | Interaction between SERTPR and stressful life events on response to antidepressant treatment | 1.0 | 43 | Citations (PDF) |
| 519 | Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study | 1.0 | 49 | Citations (PDF) |
| 520 | Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects | 1.0 | 27 | Citations (PDF) |
| 521 | Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment | 1.0 | 13 | Citations (PDF) |
| 522 | The socio-economical burden of schizophrenia: A simulation of cost-offset of early intervention program in Italy | 0.3 | 21 | Citations (PDF) |
| 523 | P.2.c.004 Basic fibroblast growth factor (FGF2) gene polymorphisms could contribute to SSRIs treatment response and tolerability | 1.0 | 0 | Citations (PDF) |
| 524 | Mindfulness-Based Stress Reduction for Stress Management in Healthy People: A Review and Meta-Analysis | 2.5 | 1,397 | Citations (PDF) |
| 525 | Treatment-Emergent Sexual Dysfunction Related to Antidepressants | 2.0 | 520 | Citations (PDF) |
| 526 | Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders | 1.7 | 42 | Citations (PDF) |
| 527 | Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients | 1.7 | 70 | Citations (PDF) |
| 528 | Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors | 1.3 | 25 | Citations (PDF) |
| 529 | Lack of Association between Interleukin-1 alpha rs1800587 Polymorphism and Alzheimer's Disease in Two Independent European Samples | 2.7 | 26 | Citations (PDF) |
| 530 | HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory | 2.2 | 31 | Citations (PDF) |
| 531 | No influence of FAT polymorphisms in response to aripiprazole | 2.2 | 6 | Citations (PDF) |
| 532 | Genetics of Mood Disorders 2009, , 125-133 | | 1 | Citations (PDF) |
| 533 | Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia | 3.0 | 43 | Citations (PDF) |
| 534 | NOS‐I and ‐III gene variants are differentially associated with facets of suicidal behavior and aggression‐related traits | 1.8 | 53 | Citations (PDF) |
| 535 | Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior | 1.8 | 19 | Citations (PDF) |
| 536 | Serotonin transporter gene and adverse life events in adult ADHD | 1.8 | 41 | Citations (PDF) |
| 537 | The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions | 8.4 | 176 | Citations (PDF) |
| 538 | Temperament and character of suicide attempters | 3.1 | 66 | Citations (PDF) |
| 539 | DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients | 2.0 | 15 | Citations (PDF) |
| 540 | Estrogen receptor gene 1 variants are not associated with suicidal behavior | 3.4 | 15 | Citations (PDF) |
| 541 | Association between GSK-3β -50T/C polymorphism and personality and psychotic symptoms in mood disorders | 3.4 | 43 | Citations (PDF) |
| 542 | Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: One-month prospective evaluation | 3.4 | 9 | Citations (PDF) |
| 543 | Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder | 4.2 | 16 | Citations (PDF) |
| 544 | ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder | 4.2 | 131 | Citations (PDF) |
| 545 | Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients | 4.2 | 30 | Citations (PDF) |
| 546 | Acute antipyschotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes | 4.2 | 44 | Citations (PDF) |
| 547 | Psychometric characteristic of the Italian version of the Temperament and Character Inventory—Revised, personality, psychopathology, and attachment styles | 4.5 | 84 | Citations (PDF) |
| 548 | P.1.a.006 Serotonin transporter: an example of gene influence on human behaviour | 1.0 | 0 | Citations (PDF) |
| 549 | P.1.a.007 A genetic assessment of antipsychotic and antidepressant cardiac iatrogenicity: focus on the proarrhythmic profile | 1.0 | 0 | Citations (PDF) |
| 550 | P.2.a.015 Weight gain and antidepressants: a comprehensive review and meta analysis | 1.0 | 1 | Citations (PDF) |
| 551 | P.2.c.005 Meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder | 1.0 | 1 | Citations (PDF) |
| 552 | Predictors of response to pharmacotherapy in mood and anxiety disorders: Commonalities, differences and indications | 0.3 | 0 | Citations (PDF) |
| 553 | HTR1A polymorphisms are associated with the antidepressant response in patients with major depressive disorder | 0.3 | 0 | Citations (PDF) |
| 554 | Serotonin receptor 1a, 2a, 2c and CONT SNPs and personality traits in suicide attempters and controls | 0.3 | 0 | Citations (PDF) |
| 555 | Serotonin transporter gene and adverse life events in adult ADHD | 0.3 | 0 | Citations (PDF) |
| 556 | <i>TAAR6</i>variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study | 0.3 | 14 | Citations (PDF) |
| 557 | Pharmacogenetic of DTNBP1 and HSP70 variations in the bipolar acute treatment with mood stabilizers | 0.3 | 0 | Citations (PDF) |
| 558 | 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies | 2.0 | 60 | Citations (PDF) |
| 559 | The serotonin transporter gene and effectiveness of SSRIs | 3.3 | 25 | Citations (PDF) |
| 560 | Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia | 2.5 | 6 | Citations (PDF) |
| 561 | Pharmacogenetics of antidepressant response: An update | 3.9 | 39 | Citations (PDF) |
| 562 | Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder | 8.4 | 418 | Citations (PDF) |
| 563 | Pharmacogenetics of Antidepressant Response 2008, , 315-353 | | 2 | Citations (PDF) |
| 564 | Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder | 1.7 | 4 | Citations (PDF) |
| 565 | Personality and Genetics | 1.0 | 7 | Citations (PDF) |
| 566 | HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies | 2.5 | 144 | Citations (PDF) |
| 567 | Genetics of Alzheimer's Disease. A Rapidly Evolving Field | 2.7 | 93 | Citations (PDF) |
| 568 | Reply to Comments by Dr Rico-Villademoros | 2.0 | 2 | Citations (PDF) |
| 569 | Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy | 1.3 | 28 | Citations (PDF) |
| 570 | Serotonin transporter gene influences the time course of improvement of “core” depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders | 3.4 | 47 | Citations (PDF) |
| 571 | Clinical prediction of antidepressant response in mood disorders: Linear multivariate vs. neural network models | 3.4 | 25 | Citations (PDF) |
| 572 | Antidepressant response in the elderly | 3.4 | 21 | Citations (PDF) |
| 573 | Heat-shock protein-70 genes and response to antidepressants in major depression | 4.2 | 42 | Citations (PDF) |
| 574 | 5-HT2A SNPs and the Temperament and Character Inventory | 4.2 | 32 | Citations (PDF) |
| 575 | How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes | 1.0 | 57 | Citations (PDF) |
| 576 | Factors associated to resistant depression | 0.3 | 0 | Citations (PDF) |
| 577 | P.1.02 Interaction between SERTPR and stressful life events on response to antidepressant treatment | 1.0 | 0 | Citations (PDF) |
| 578 | S.3.2 Genetic predictors of illness and treatment response | 1.0 | 0 | Citations (PDF) |
| 579 | S.02.05 European research programme on treatment resistant depression | 1.0 | 0 | Citations (PDF) |
| 580 | Further evidence of MAO-A gene variants associated with bipolar disorder | 1.8 | 18 | Citations (PDF) |
| 581 | <i>HTR2C</i> and <i>HTR1A</i> gene variants in German and Italian suicide attempters and completers | 1.8 | 73 | Citations (PDF) |
| 582 | Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder | 1.8 | 30 | Citations (PDF) |
| 583 | Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression | 1.8 | 186 | Citations (PDF) |
| 584 | Tachykinin receptor 1 variants associated with aggression in suicidal behavior | 1.8 | 17 | Citations (PDF) |
| 585 | Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment | 1.8 | 46 | Citations (PDF) |
| 586 | Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases | 2.6 | 10 | Citations (PDF) |
| 587 | HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study | 8.4 | 34 | Citations (PDF) |
| 588 | A neural network model for combining clinical predictors of antidepressant response in mood disorders | 4.8 | 21 | Citations (PDF) |
| 589 | Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders | 2.0 | 112 | Citations (PDF) |
| 590 | Pharmacogenetic studies in depression: a proposal for methodologic guidelines | 3.1 | 74 | Citations (PDF) |
| 591 | Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder | 2.9 | 475 | Citations (PDF) |
| 592 | S.03.05 Clinical pharmacogenetic studies in the treatment of depression | 1.0 | 0 | Citations (PDF) |
| 593 | P.2.g.007 Influence of clock gene polymorphism on sleep-wake cycle in depressed bipolar patients: an actigraphic study | 1.0 | 0 | Citations (PDF) |
| 594 | Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome | 2.0 | 11 | Citations (PDF) |
| 595 | Pooling pharmacogenetic studies on the serotonin transporter: A mega-analysis | 3.4 | 35 | Citations (PDF) |
| 596 | Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: The role of clinical, psychosocial and genetic variables | 4.2 | 18 | Citations (PDF) |
| 597 | Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants | 1.4 | 48 | Citations (PDF) |
| 598 | Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case–control study | 1.4 | 5 | Citations (PDF) |
| 599 | Catechol-O-methyltransferase gene variants in mood disorders in the Italian population | 1.4 | 29 | Citations (PDF) |
| 600 | Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis | 3.2 | 35 | Citations (PDF) |
| 601 | Ethical problems in pharmacogenetic studies of psychiatric disorders | 3.1 | 13 | Citations (PDF) |
| 602 | Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin | 4.8 | 94 | Citations (PDF) |
| 603 | Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre | 3.3 | 23 | Citations (PDF) |
| 604 | Influence of postpartum onset on the course of mood disorders | 3.3 | 22 | Citations (PDF) |
| 605 | Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression | 3.9 | 50 | Citations (PDF) |
| 606 | Serotonin Transporter Gene Variants and Behavior: A Comprehensive Review | 2.0 | 192 | Citations (PDF) |
| 607 | Major depressive disorders: depressive disorders 2006, , 45-73 | | 0 | Citations (PDF) |
| 608 | Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients | 8.4 | 500 | Citations (PDF) |
| 609 | Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression | 2.0 | 37 | Citations (PDF) |
| 610 | Genetics of Mood Disorders 2005, , 35-75 | | 1 | Citations (PDF) |
| 611 | Two new rare variants in the circadian “clock” gene may influence sleep pattern | 2.2 | 17 | Citations (PDF) |
| 612 | Pharmacogenetics in the treatment of depression: pharmacodynamic studies | 1.3 | 74 | Citations (PDF) |
| 613 | Dopamine transporter haplotype and attention-deficit hyperactivity disorder | 8.4 | 23 | Citations (PDF) |
| 614 | Profiles of “manic” symptoms in bipolar I, bipolar II and major depressive disorders | 4.8 | 99 | Citations (PDF) |
| 615 | Components of self-esteem in affective patients and non-psychiatric controls | 4.8 | 29 | Citations (PDF) |
| 616 | 5-HT1A polymorphism and self-transcendence in mood disorders | 1.8 | 28 | Citations (PDF) |
| 617 | Insomnia improvement during antidepressant treatment andCLOCK gene polymorphism | 1.8 | 153 | Citations (PDF) |
| 618 | Genes involved in Alzheimer's disease, a survey of possible candidates | 2.7 | 32 | Citations (PDF) |
| 619 | P.3.06 A glycogen synthase kinase 3-ß -50 T/CSNP influences long-term response to lithium salts in bipolar illness | 1.0 | 0 | Citations (PDF) |
| 620 | Cognitive Status, Depressive Symptoms, and Health Status as Predictors of Functional Disability Among Elderly Persons With Low-to-Moderate Education: The Faenza Community Aging Study | 1.0 | 17 | Citations (PDF) |
| 621 | Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β −50 T/C SNP | 2.0 | 187 | Citations (PDF) |
| 622 | No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia | 2.3 | 15 | Citations (PDF) |
| 623 | Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia | 2.3 | 37 | Citations (PDF) |
| 624 | The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments | 4.2 | 106 | Citations (PDF) |
| 625 | Social adjustment could be associated with the serotonin transporter gene in remitted patients with mood disorders and healthy subjects | 3.4 | 11 | Citations (PDF) |
| 626 | New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects | 2.5 | 105 | Citations (PDF) |
| 627 | The 5-HT2C receptor as a target for mood disorders | 3.7 | 52 | Citations (PDF) |
| 628 | Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study | 3.6 | 78 | Citations (PDF) |
| 629 | The pharmacogenomics of selective serotonin reuptake inhibitors | 3.1 | 68 | Citations (PDF) |
| 630 | Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders | 3.1 | 56 | Citations (PDF) |
| 631 | Social adjustment and self-esteem of bipolar patients: a multicentric study | 4.8 | 95 | Citations (PDF) |
| 632 | From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes | 3.0 | 53 | Citations (PDF) |
| 633 | Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder | 3.0 | 45 | Citations (PDF) |
| 634 | Neural network analysis in pharmacogenetics of mood disorders | 2.0 | 51 | Citations (PDF) |
| 635 | Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders | 2.2 | 68 | Citations (PDF) |
| 636 | Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study | 2.0 | 9 | Citations (PDF) |
| 637 | Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population | 3.4 | 36 | Citations (PDF) |
| 638 | Dimensions of major psychoses: a confirmatory factor analysis of six competing models | 3.4 | 58 | Citations (PDF) |
| 639 | Depressive syndrome in major psychoses: a study on 1351 subjects | 3.4 | 67 | Citations (PDF) |
| 640 | Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population | 3.4 | 33 | Citations (PDF) |
| 641 | A single nucleotide polymorphism in glycogen synthase kinase 3-β promoter gene influences onset of illness in patients affected by bipolar disorder | 2.0 | 161 | Citations (PDF) |
| 642 | DRD4 exon 3 variants are not associated with symptomatology of major psychoses in a German population | 2.0 | 5 | Citations (PDF) |
| 643 | A glycogen synthase kinase 3-β promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression | 2.0 | 192 | Citations (PDF) |
| 644 | P.1.05 HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter genetic association study | 1.0 | 0 | Citations (PDF) |
| 645 | Monocyte chemoattractant protein-1 promoter –2518 polymorphism and schizophrenia in the Korean population | 1.4 | 15 | Citations (PDF) |
| 646 | Pharmacogenetics of selective serotonin reuptake inhibitor response | 5.8 | 32 | Citations (PDF) |
| 647 | The C(–1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings | 2.0 | 122 | Citations (PDF) |
| 648 | Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment | 2.0 | 45 | Citations (PDF) |
| 649 | Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population | 1.4 | 31 | Citations (PDF) |
| 650 | Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study | 8.4 | 138 | Citations (PDF) |
| 651 | The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach | 1.2 | 2 | Citations (PDF) |
| 652 | Influence of <i>CLOCK</i> gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression | 1.8 | 294 | Citations (PDF) |
| 653 | Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and <i>CLOCK</i> gene polymorphism | 1.8 | 237 | Citations (PDF) |
| 654 | Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population | 3.2 | 17 | Citations (PDF) |
| 655 | Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population | 3.2 | 27 | Citations (PDF) |
| 656 | Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study | 1.0 | 20 | Citations (PDF) |
| 657 | Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene | 1.5 | 83 | Citations (PDF) |
| 658 | TNFB polymorphism may be associated with schizophrenia in the Korean population | 2.4 | 18 | Citations (PDF) |
| 659 | SSRIs antidepressant activity is influenced by Gβ3 variants | 1.0 | 88 | Citations (PDF) |
| 660 | P.1.025 Fluvoxamine response in nondemented elderly compared to younger depressives | 1.0 | 0 | Citations (PDF) |
| 661 | P.1.115 CLOCK gene and circadian mood fluctuations in bipolar depression | 1.0 | 0 | Citations (PDF) |
| 662 | P.1.123 CLOCK gene influences insomnia during antidepressant treatment | 1.0 | 0 | Citations (PDF) |
| 663 | Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population | 4.2 | 22 | Citations (PDF) |
| 664 | Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder | 4.2 | 34 | Citations (PDF) |
| 665 | Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression | 3.4 | 23 | Citations (PDF) |
| 666 | Gene–environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms | 3.4 | 77 | Citations (PDF) |
| 667 | Title is missing! | 1.4 | 7 | Citations (PDF) |
| 668 | Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case???control study | 1.4 | 22 | Citations (PDF) |
| 669 | Possible association between ???G308A tumour necrosis factor-?? gene polymorphism and major depressive disorder in the Korean population | 1.4 | 109 | Citations (PDF) |
| 670 | Comparison of Response to Fluvoxamine in Nondemented Elderly Compared to Younger Patients Affected by Major Depression | 2.0 | 26 | Citations (PDF) |
| 671 | Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders | 1.4 | 27 | Citations (PDF) |
| 672 | Excess of allele1 for α3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study | 8.4 | 51 | Citations (PDF) |
| 673 | Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity | 2.0 | 91 | Citations (PDF) |
| 674 | Serotonin transporter gene (5-HTTLPR) and major psychoses | 8.4 | 82 | Citations (PDF) |
| 675 | Clinical and demographic features of mood disorder subtypes | 3.4 | 60 | Citations (PDF) |
| 676 | Rapid cycling mood disorder: Clinical and demographic features | 4.5 | 22 | Citations (PDF) |
| 677 | Seasonal variations of lithium plasma levels | 3.4 | 15 | Citations (PDF) |
| 678 | Pharmacogenetics in affective disorders | 4.4 | 55 | Citations (PDF) |
| 679 | Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders | 2.2 | 52 | Citations (PDF) |
| 680 | Family‐based association study of 5‐HTTLPR, TPH, MAO‐A, and DRD4 polymorphisms in mood disorders | 2.2 | 57 | Citations (PDF) |
| 681 | Pharmacogenetics of lithium prophylaxis in mood disorders: Analysis of COMT, MAO‐A, and Gβ3 variants | 2.2 | 50 | Citations (PDF) |
| 682 | Association study of MAO‐A, COMT, 5‐HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders | 2.2 | 48 | Citations (PDF) |
| 683 | Serotonin transporter gene (5-HTTLPR) and major psychoses | 8.4 | 6 | Citations (PDF) |
| 684 | Tryptophan hydroxylase gene associated with paroxetine antidepressant activity | 1.0 | 104 | Citations (PDF) |
| 685 | Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study | 1.5 | 66 | Citations (PDF) |
| 686 | Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression | 1.5 | 219 | Citations (PDF) |
| 687 | Tryptophan hydroxylase gene and major psychoses | 3.4 | 48 | Citations (PDF) |
| 688 | No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors | 3.4 | 54 | Citations (PDF) |
| 689 | Major psychoses symptomatology: factor analysis of 2241 psychotic subjects | 3.0 | 40 | Citations (PDF) |
| 690 | DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: A study on 2,011 affected subjects | 2.2 | 61 | Citations (PDF) |
| 691 | Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity | 8.4 | 171 | Citations (PDF) |
| 692 | Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder | 8.4 | 152 | Citations (PDF) |
| 693 | Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders | 3.1 | 41 | Citations (PDF) |
| 694 | Serotonin transporter gene associated with lithium prophylaxis in mood disorders | 3.1 | 107 | Citations (PDF) |
| 695 | "Dr. Zanardi and Colleagues Reply" | 2.9 | 1 | Citations (PDF) |
| 696 | Melancholic features and response to lithium prophylaxis in mood disorders | 3.9 | 19 | Citations (PDF) |
| 697 | Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia 2000, 96, 84-87 | | 20 | Citations (PDF) |
| 698 | A European multicenter association study ofHTR2A receptor polymorphism in bipolar affective disorder 2000, 96, 136-140 | | 39 | Citations (PDF) |
| 699 | Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders 2000, 96, 161-166 | | 19 | Citations (PDF) |
| 700 | Effect of reboxetine augmentation in SSRI resistant patients 2000, 15, 143-145 | | 17 | Citations (PDF) |
| 701 | Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses | 8.4 | 61 | Citations (PDF) |
| 702 | Linkage of mood disorders with D2, D3 and TH genes: a multicenter study | 4.8 | 28 | Citations (PDF) |
| 703 | Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders | 3.1 | 66 | Citations (PDF) |
| 704 | Patterns of symptom improvement during antidepressant treatment of delusional depression | 3.4 | 31 | Citations (PDF) |
| 705 | Impact of clinical variables on illness time course in mood disorders | 3.4 | 28 | Citations (PDF) |
| 706 | A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder | 2.2 | 2 | Citations (PDF) |
| 707 | Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression | 2.9 | 223 | Citations (PDF) |
| 708 | Adaptación social y autoestima en pacientes con remisión de trastorno del estado de ánimo | 0.0 | 0 | Citations (PDF) |
| 709 | Dr. Benedetti and Colleagues Reply | 10.1 | 0 | Citations (PDF) |
| 710 | Genetic Variants of Dopamine Receptor D4 and Psychopathology | 4.3 | 35 | Citations (PDF) |
| 711 | Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders | 8.4 | 98 | Citations (PDF) |
| 712 | Symptomatologic analysis of psychotic and non-psychotic depression | 4.8 | 63 | Citations (PDF) |
| 713 | Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression | 4.8 | 53 | Citations (PDF) |
| 714 | Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders11This work was partially supported by the BIOMED 2 grant BMH4-CT97-2307. | 3.1 | 82 | Citations (PDF) |
| 715 | No interaction of GABAA alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses 1999, 88, 44-49 | | 18 | Citations (PDF) |
| 716 | Dopamine D2 receptor gene not associated with symptomatology of mood disorders | 2.2 | 16 | Citations (PDF) |
| 717 | Dopamine D3 receptor gene not associated with symptomatology of major psychoses 1999, 88, 476-480 | | 15 | Citations (PDF) |
| 718 | No interaction between serotonin transporter gene and dopamine receptorD4 gene in symptomatology of major psychoses 1999, 88, 481-485 | | 11 | Citations (PDF) |
| 719 | Dopamine receptorD4 gene is not associated with major psychoses 1999, 88, 486-491 | | 25 | Citations (PDF) |
| 720 | Outcome of affective psychosis 1999, 10, 50-54 | | 6 | Citations (PDF) |
| 721 | Serotonin transporter gene not associated with psychotic symptomatology of mood disorders | 3.4 | 24 | Citations (PDF) |
| 722 | No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders | 3.4 | 14 | Citations (PDF) |
| 723 | Dopamine receptor D2 and D4 genes, GABAA alpha-1 subunit gene and response to lithium prophylaxis in mood disorders | 3.4 | 67 | Citations (PDF) |
| 724 | Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation | 3.4 | 28 | Citations (PDF) |
| 725 | Factor analysis of delusional disorder symptomatology | 4.5 | 42 | Citations (PDF) |
| 726 | Clinical and demographic features of psychotic and nonpsychotic depression | 4.5 | 34 | Citations (PDF) |
| 727 | Serotonin transporter gene is not associated with symptomatology of schizophrenia | 2.4 | 35 | Citations (PDF) |
| 728 | Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia | 2.4 | 6 | Citations (PDF) |
| 729 | Social adjustment and self-esteem in remitted patients with mood disorders | 0.3 | 39 | Citations (PDF) |
| 730 | Factor Analysis of Mania | 14.5 | 36 | Citations (PDF) |
| 731 | Influence of a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene on the Effects of Total Sleep Deprivation in Bipolar Depression | 10.1 | 152 | Citations (PDF) |
| 732 | Tyrosine hydroxylase gene in linkage disequilibrium with mood disorders | 8.4 | 19 | Citations (PDF) |
| 733 | Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees | 3.1 | 154 | Citations (PDF) |
| 734 | Analysis of depressive symptomatology in mood disorders | 3.9 | 35 | Citations (PDF) |
| 735 | Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder 1998, 81, 127-130 | | 56 | Citations (PDF) |
| 736 | Dopamine receptor D4 gene is associated with delusional symptomatology in mood disorders | 3.4 | 36 | Citations (PDF) |
| 737 | Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D4 and the serotonin transporter genes | 3.4 | 7 | Citations (PDF) |
| 738 | Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia | 2.4 | 42 | Citations (PDF) |
| 739 | Psychopathology of dysthymia | 0.3 | 0 | Citations (PDF) |
| 740 | Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders | 2.0 | 45 | Citations (PDF) |
| 741 | European Collaborative Project on Affective Disorders | 1.4 | 41 | Citations (PDF) |
| 742 | GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders | 1.4 | 22 | Citations (PDF) |
| 743 | S.17.05 Molecular genetics of bipolar disorders: Implication for psychotropic drugs | 1.0 | 6 | Citations (PDF) |
| 744 | Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics | 1.7 | 15 | Citations (PDF) |
| 745 | Identification of symptomatologic patterns common to major psychoses: Proposal for a phenotype definition | 2.2 | 61 | Citations (PDF) |
| 746 | Symptomatologic structure extraction of major psychosis and association with DRD4 exon 1 and 3 variants | 4.0 | 0 | Citations (PDF) |
| 747 | Positive association between bipolar affective disorder and tyrosine hydroxylase gene | 4.0 | 0 | Citations (PDF) |
| 748 | Low-dose buprenorphine detoxification in long term methadone addicts | 1.9 | 5 | Citations (PDF) |
| 749 | Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine | 3.1 | 74 | Citations (PDF) |
| 750 | Antidepressant induced weight gain | 0.1 | 6 | Citations (PDF) |
